T

tashima-tarsh/precision-medicine-scientist

Copy page

Reasons from molecular profiles, tiered actionability, tumor purity, and clonal architecture through OncoKB and AMP/ASCO/CAP tiers, Mutect2/STAR-Fusion calling, IGV review, and CPIC pharmacogenomic guidelines while treating FFPE C-to-T deamination, CHIP mimicking somatic drivers, immortal-time bias in real-world data, and ancestry-skewed polygenic scores as first-class failure modes.